Welcome to our dedicated page for Progyny SEC filings (Ticker: PGNY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
When you research Progyny, the first numbers you chase are live-birth success rates, employer contract renewals, and network clinic costs. Those details hide inside dense SEC documents, not glossy press releases. This page gathers every Progyny SEC filing explained simply, so you no longer sift through hundreds of pages to verify margin trends or Smart Cycle utilization rates.
Use our AI-powered summaries to jump directly to what matters: the Progyny annual report 10-K simplified spotlights outcome statistics and revenue per member, while the latest Progyny quarterly earnings report 10-Q filing breaks down reimbursement shifts and new client wins. Sudden contract announcements? The Progyny 8-K material events explained section flags them within minutes of hitting EDGAR. If you’re tracking leadership incentives, our system streams Progyny Form 4 insider transactions real-time, alerting you to every Progyny executive stock transactions Form 4.
Here’s how professionals use the page:
- Compare quarter-over-quarter embryo transfer success rates with one-click Progyny earnings report filing analysis.
- Monitor governance changes through the Progyny proxy statement executive compensation link to gauge retention costs.
- Stay ahead of market moves with instant notifications on Progyny insider trading Form 4 transactions.
Allison Swartz, EVP and General Counsel of Progyny, Inc. (PGNY), reported two transactions on 08/28/2025. She sold 2,398 shares of Common Stock under a Rule 10b5-1 plan at $22.96 per share and had 1,352 shares withheld to cover taxes on vested restricted stock units at an effective price of $23.02 per share. The filings show total beneficial ownership following these transactions of 78,345 shares. The 10b5-1 plan was entered on May 13, 2025, and the Form 4 was signed via attorney-in-fact on 09/02/2025. The report reflects routine disposition and tax-withholding actions by an officer rather than derivative activity.
Progyny, Inc. (PGNY) filed a Form 144 reporting a proposed sale of 2,398 common shares for an aggregate market value of $55,058.08. The shares are to be sold through Fidelity Brokerage Services on the NASDAQ with an approximate sale date of 08/28/2025. The filing shows 85,982,409 shares outstanding for the class listed.
The securities were acquired on 08/28/2025 through restricted stock vesting and the consideration is listed as compensation. The filer reports no securities sold in the past three months and includes the standard representation that the selling person does not possess undisclosed material adverse information.
Progyny director GORDON KEVIN K reported a sale of 2,500 common shares on 08/11/2025 at a price of $22.035. The filing shows 12,501 shares are beneficially owned indirectly by the Kevin Gordon Revocable Declaration of Trust, for which the reporting person serves as trustee.
The form's explanation states 5,147 shares were transferred into that Trust on June 2, 2025 from shares previously reported as directly held. The filing also includes a table entry listing 8,026 shares with a disposition marker but no date or price shown for that line.
Progyny (PGNY) filed a Form 144 notifying a proposed sale of 2,500 shares of its common stock, with an aggregate market value of $55,087.50, through Fidelity Brokerage Services LLC on 08/11/2025. The shares were acquired on 10/24/2021 via restricted stock vesting and were granted as compensation; the filer reports no securities sold in the past three months.
The filing includes the issuer's outstanding share count of 85,982,409, making the proposed sale a very small fraction of outstanding stock. The notice includes the filer’s representation that no undisclosed material adverse information about the issuer is known.
Progyny (PGNY) filed its Q2-25 10-Q showing solid top-line momentum and margin expansion, tempered by higher opex and tax expense.
- Revenue rose 9.5% YoY to $332.9 m; pharmacy contributed 36% while core fertility benefits grew 10.5%. 1H-25 revenue is up 12.9% to $656.9 m.
- Gross profit improved 15.7% to $79.0 m; gross margin expanded 130 bp to 23.7% as case-rate pricing and pharmacy rebates offset service-cost inflation.
- Operating income increased 17.7% to $24.4 m; however, a higher effective tax rate (36.8% vs 34.2%) limited net income growth to 3.8% ($17.1 m, $0.19 diluted EPS).
- For 1H-25, net income slipped 3.6% to $32.2 m, but diluted EPS rose to $0.36 on a 10% lower share count following 2024 buybacks.
- Cash & M-secs stand at $305.1 m, up $18.1 m YoY; operating cash flow strengthened 28% to $105.3 m. No debt; a new $200 m undrawn revolver was signed 1 Jul 25.
- Balance sheet: current ratio 2.7x; equity climbed 22% to $515.0 m. Accounts receivable (+16%) and payables (+48%) rose with volume.
- Operations: ART cycles grew 8.8% to 16,938 while overall member utilization held at 0.55%. Client count reached 542 covering 6.8 m lives.
- M&A: closed $10.5 m Benefit Bump acquisition in Jan-25; integration ongoing.
Overall, PGNY continues to outpace the fertility-benefits market, generating healthy cash and maintaining a debt-free profile, though investors should watch rising opex, receivables exposure and tax headwinds.
FAQ
What is the current stock price of Progyny (PGNY)?
What is the market cap of Progyny (PGNY)?
